All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Sanofi Begins Dosing of DNL758 in Phase Ib Covid-19 Trial

Lead Product(s): DNL758

Therapeutic Area: Infections and Infectious Diseases Product Name: SAR443122

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Denali Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 30, 2020

Details:

Dosing of DNL758 has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19.